Key points are not available for this paper at this time.
Initial histology, age, KPS, and corticosteroid use are prognostic for survival in recurrent glioma patients. To allow comparisons across phase II trials, enrollment criteria may need to be restricted.
Carson et al. (2007) studied this question.